Skip to main content
SpringerLink
Log in

Treatment of Advanced Pancreatic Carcinoma

  • Chapter
  • First Online:
Textbook of Gastrointestinal Oncology

  • 848 Accesses

Abstract

More than 85% of pancreatic cancer is pancreatic ductal adenocarcinoma; the rest is comprised of rare histologic forms such as neuroendocrine tumor and other less common histologic variants. More than 75% of patients die within a year of diagnosis. In addition to the aggressive biology, lack of effective treatments is a major reason why a cancer that ranks 12th in incidence ranks so high in cancer-related mortality. Surgical resection of pancreas cancer remains the only treatment modality with a potential for cure. However, less than 20% of patients with pancreatic adenocarcinoma present with surgically operable tumors. Nearly half of the patients have clinical or radiographic evidence of metastatic disease upon initial presentation. Hence, many patients with pancreatic adenocarcinoma present with an incurable disease. The 5-year survival rate for patients with pancreatic adenocarcinoma is estimated to be less than 5%. In this chapter, we discuss available treatments and explore newer therapeutic approaches being evaluated in metastatic pancreatic adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  3. Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(4):843–52.

    Article  CAS  PubMed  Google Scholar 

  4. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer (Oxford, England: 1990). 2011;47(13):1928–37.

    Article  Google Scholar 

  5. Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. Cigarette smoking and pancreatic cancer: an analysis from the international pancreatic cancer case-control consortium (panc4). Ann Oncol. 2012;23(7):1880–8.

    Article  CAS  PubMed  Google Scholar 

  6. Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the international pancreatic cancer case-control consortium (panc4). Ann Oncol. 2012;23(11):2964–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, et al. Exomic sequencing identifies palb2 as a pancreatic cancer susceptibility gene. Science (New York, NY). 2009;324(5924):217.

    Article  CAS  Google Scholar 

  8. Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, et al. The incidence of pancreatic cancer in brca1 and brca2 mutation carriers. Br J Cancer. 2012;107(12):2005–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rebours V, Boutron-Ruault MC, Schnee M, Ferec C, Maire F, Hammel P, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103(1):111–9.

    Article  PubMed  Google Scholar 

  10. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with lynch syndrome. JAMA. 2009;302(16):1790–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial peutz-jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.

    Article  CAS  PubMed  Google Scholar 

  12. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  13. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  CAS  Google Scholar 

  14. Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, et al. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016;115(2):188–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.

    Article  CAS  PubMed  Google Scholar 

  16. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol. 2007;25(15):1960–6.

    Article  CAS  PubMed  Google Scholar 

  17. Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson GS, et al. Updated overall survival analysis of napoli-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. ASCO Meet Abstr. 2016;34(4_suppl):417.

    Google Scholar 

  18. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the conko-003 trial. J Clin Oncol. 2014;32(23):2423–9.

    Article  CAS  PubMed  Google Scholar 

  19. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (xelox) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008;113(8):2046–52.

    Article  CAS  PubMed  Google Scholar 

  20. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified folfiri.3 vs modified folfox as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101(10):1658–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ghosn M, Farhat F, Kattan J, Younes F, Moukadem W, Nasr F, et al. Folfox-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am J Clin Oncol. 2007;30(1):15–20.

    Article  CAS  PubMed  Google Scholar 

  22. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, et al. Capecitabine plus oxaliplatin (capox) versus capecitabine plus gemcitabine (capgem) versus gemcitabine plus oxaliplatin (mgemox): final results of a multicenter randomized phase ii trial in advanced pancreatic cancer. Ann Oncol. 2008;19(2):340–7.

    Article  CAS  PubMed  Google Scholar 

  23. Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol. 2009;32(1):44–8.

    Article  CAS  PubMed  Google Scholar 

  24. Zaanan A, Trouilloud I, Markoutsaki T, Gauthier M, Dupont-Gossart AC, Lecomte T, et al. Folfox as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the firgem study. BMC Cancer. 2014;14:441.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chung JW, Jang HW, Chung MJ, Park JY, Park SW, Chung JB, et al. Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer. Hepatogastroenterology. 2013;60(122):363–7.

    CAS  PubMed  Google Scholar 

  26. Gill S, Ko Y-JJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. Pancreox: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34:3914–20.

    Article  CAS  PubMed  Google Scholar 

  27. Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardiere C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after folfirinox failure: an ageo prospective multicentre cohort. Br J Cancer. 2015;113(7):989–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G. Irinotecan plus bolus/infusional 5-fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the gruppo oncologico italia meridionale. Am J Clin Oncol. 2010;33(5):461–4.

    Article  CAS  PubMed  Google Scholar 

  29. Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefevre L, Bonnetain F, et al. Folfiri regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol. 2012;18(33):4533–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene. 2013;32(45):5253–60.

    Article  CAS  PubMed  Google Scholar 

  31. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. Kegg as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457–62.

    Article  CAS  PubMed  Google Scholar 

  32. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. Kegg: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–61.

    Article  CAS  PubMed  Google Scholar 

  33. Hruban RH, Wilentz RE, Maitra A. Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol Med. 2005;103:1–13.

    PubMed  Google Scholar 

  34. di Magliano MP, Logsdon CD. Roles for kras in pancreatic tumor development and progression. Gastroenterology. 2013;144(6):1220–9.

    Article  CAS  PubMed  Google Scholar 

  35. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. Kras: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39(2):91–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, et al. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol. 2017;3:516–22.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial s0205. J Clin Oncol. 2010;28(22):3605–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, et al. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (swog s0727). Cancer. 2014;120(19):2980–5.

    Article  CAS  PubMed  Google Scholar 

  39. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress her-2/neu. Cancer Invest. 2004;22(5):706–12.

    Article  CAS  PubMed  Google Scholar 

  40. Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with Her2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012;106(6):1033–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Safran H, Miner T, Bahary N, Whiting S, Lopez CD, Sun W, et al. Lapatinib and gemcitabine for metastatic pancreatic cancer. a phase II study. Am J Clin Oncol. 2011;34(1):50–2.

    Article  CAS  PubMed  Google Scholar 

  42. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral mek1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730–8.

    Article  CAS  PubMed  Google Scholar 

  43. Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA 3rd, Patnaik A, Jones SF, et al. A phase IB trial of the oral mek inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol. 2015;26(1):58–64.

    Article  CAS  PubMed  Google Scholar 

  44. Cohen DJ, Leichman LP, Love E, Ryan T, Leichman CG, Newman E, et al. Phase II study of sorafenib with gemcitabine and erlotinib (ges) in first-line advanced pancreatic cancer. J Clin Oncol (Meeting Abstracts). 2011;29(Suppl 4):abstract 266.

    Article  Google Scholar 

  45. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer (Oxford, England: 1990). 2013;49(12):2633–42.

    Article  CAS  Google Scholar 

  47. Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2015;33(13):1475–81.

    Article  CAS  PubMed  Google Scholar 

  48. Cutsem EV, Lenz H-J, Furuse J, Tabernero J, Heinemann V, Ioka T, et al. Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: primary analysis of the randomized, double-blind phase III maestro study. J Clin Oncol (Meeting Abstracts). 2016;34(Suppl 4S):abstract 193.

    Article  Google Scholar 

  49. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425(6960):851–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res. 2008;14(19):5995–6004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455(7211):406–10.

    Article  CAS  PubMed  Google Scholar 

  52. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (New York, NY). 2009;324(5933):1457–61.

    Article  CAS  Google Scholar 

  53. Lou K-J. Stromal uncertainties in pancreatic cancer. Sci Bus eXch. 2014;7(23):1–3.

    Google Scholar 

  54. Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014;20(23):5937–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–20.

    Article  CAS  PubMed  Google Scholar 

  57. Hingorani SR, Harris WP, Hendifar AE, Bullock AJ, Wu XW, Huang Y, et al. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-ha tumors: interim results of a randomized phase II study. J Clin Oncol (Meeting Abstracts). 2015;33(Suppl):abstract 4006.

    Article  Google Scholar 

  58. Therapeutics H. A study of pegylated recombinant human hyaluronidase in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in participants with hyaluronan-high stage iv previously untreated pancreatic ductal adenocarcinoma. Nct02715804. 2016, March 16 [cited 2017 January 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02715804?term=pegph20&rank=13.

  59. Aaronson DS, Horvath CM. A road map for those who don’t know jak-stat. Science (New York, NY). 2002;296(5573):1653–5.

    Article  CAS  Google Scholar 

  60. Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015;33(34):4039–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Hurwitz H, Cutsem EV, Bendell JC, Hidalgo M, Li C-P, Garrido M, et al. Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: Janus 1 (J1) and janus 2 (J2). J Clin Oncol (Meeting Abstracts). 2017;35(Suppl 4S):abstract 343.

    Article  Google Scholar 

  62. Goggins M, Offerhaus GJ, Hilgers W, Griffin CA, Shekher M, Tang D, et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest rer+. Am J Pathol. 1998;152(6):1501–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a pacgene study. Genet Med. 2015;17(7):569–77.

    Article  CAS  PubMed  Google Scholar 

  64. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, et al. An emerging entity: pancreatic adenocarcinoma associated with a known brca mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16(10):1397–402.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline brca1/2 mutation. J Clin Oncol. 2015;33(3):244–50.

    Article  CAS  PubMed  Google Scholar 

  67. Pishvaian MJ, Wang H, Zhuang T, He AR, Hwang JJ, Hankin A, et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). J Clin Oncol (Meeting Abstracts). 2013;31(Suppl 4):abstract 147.

    Article  Google Scholar 

  68. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393(6684):478–80.

    Article  CAS  PubMed  Google Scholar 

  69. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393(6684):480–3.

    Article  CAS  PubMed  Google Scholar 

  70. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (New York, NY). 2011;331(6024):1612–6.

    Article  CAS  Google Scholar 

  71. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013;19(22):6286–95.

    Article  CAS  PubMed  Google Scholar 

  72. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013;19(13):3404–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with folfirinox in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015;112(6):1839–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. O’Reilly EM, Sahai V, Bendell JC, Bullock AJ, LoConte NK, Hatoum H, et al. Results of a randomized phase ii trial of an anti-notch 2/3, tarextumab (omp-59r5, trxt, anti-notch2/3), in combination with nab-paclitaxel and gemcitabine (nab-p+gem) in patients (pts) with untreated metastatic pancreatic cancer (mpc). J Clin Oncol (Meeting Abstracts). 2017;35(Suppl 4S):abstract 279.

    Article  Google Scholar 

  76. Mann CD, Bastianpillai C, Neal CP, Masood MM, Jones DJ, Teichert F, et al. Notch3 and HEY-1 as prognostic biomarkers in pancreatic adenocarcinoma. PLoS One. 2012;7(12):e51119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011;23(2):286–92.

    Article  CAS  PubMed  Google Scholar 

  78. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67(19):9518–27.

    Article  CAS  PubMed  Google Scholar 

  79. Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63(11):1769–81.

    Article  CAS  PubMed  Google Scholar 

  80. Salman B, Zhou D, Jaffee EM, Edil BH, Zheng L. Vaccine therapy for pancreatic cancer. Oncoimmunology. 2013;2(12):e26662.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253(2):328–35.

    Article  PubMed  Google Scholar 

  82. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33(12):1325–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Le DT, Ko AH, Wainberg ZA, Picozzi VJ, Kindler HL, Wang-Gillam A, et al. Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study). J Clin Oncol (Meeting Abstracts). 2017;35(Suppl 4S):abstract 345.

    Article  Google Scholar 

  84. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2(7):616–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Rossi GR, Mautino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes. Cancer Res. 2005;65(22):10555–61.

    Article  CAS  PubMed  Google Scholar 

  87. Broderick JM. Pancreatic cancer vaccine falls short in phase III trial. [Website]: Onclive; 2016 [updated May 10, 2016 February 9, 2017]. Available from: http://www.onclive.com/web-exclusives/pancreatic-cancer-vaccine-falls-short-in-phase-iii-trial#sthash.nF1Uu8Ly.dpuf.

  88. Abou-Alfa GK, Chapman PB, Feilchenfeldt J, Brennan MF, Capanu M, Gansukh B, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol. 2011;34(3):321–5.

    Article  CAS  PubMed  Google Scholar 

  89. Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15(8):829–40.

    Article  CAS  PubMed  Google Scholar 

  90. PRNewswire. Therion reports results of phase 3 panvac-vf trial. [Website]: PR Newswire; 2006 [December 1, 2015]. Available from: http://www.prnewswire.com/news-releases/therion-reports-results-of-phase-3-panvac-vf-trial-and-announces-plans-for-company-sale-56997582.html.

  91. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.

    Article  CAS  PubMed  Google Scholar 

  92. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151–7.

    Article  CAS  PubMed  Google Scholar 

  93. Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 2008;268(1):98–109.

    Article  CAS  PubMed  Google Scholar 

  94. Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg. 2010;34(5):1059–65.

    Article  PubMed  Google Scholar 

  95. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Le DT, Ko AH, Wainberg ZA, Picozzi VJ, Kindler HL, Wang-Gillam A, et al. Results from a phase 2b, randomized, multicenter study of gvax pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study). J Clin Oncol (Meeting Abstracts). 2017;35(Suppl):345.

    Article  Google Scholar 

  97. Le DT, Crocenzi TS, Uram JN, Lutz ER, Laheru DA, Sugar EA, et al. Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (stellar). J Clin Oncol (Meeting Abstracts). 2015;33(Suppl):abstract TPS4148.

    Article  Google Scholar 

  98. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-pd-l1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol. 1999;94(7):1941–6.

    Article  CAS  PubMed  Google Scholar 

  100. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–5.

    CAS  PubMed  Google Scholar 

  101. Elebro J, Ben Dror L, Heby M, Nodin B, Jirstrom K, Eberhard J. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Acta Oncol. 2016;55(3):286–96.

    Article  CAS  PubMed  Google Scholar 

  102. Nordh S, Ansari D, Andersson R. Hent1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014;20(26):8482–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Gundewar C, Sasor A, Hilmersson KS, Andersson R, Ansari D. The role of sparc expression in pancreatic cancer progression and patient survival. Scand J Gastroenterol. 2015;50(9):1170–4.

    Article  CAS  PubMed  Google Scholar 

  104. Vaz J, Ansari D, Sasor A, Andersson R. Sparc: a potential prognostic and therapeutic target in pancreatic cancer. Pancreas. 2015;44(7):1024–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, et al. UGT1A1∗6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in asians. Cancer Chemother Pharmacol. 2014;73(3):551–60.

    Article  CAS  PubMed  Google Scholar 

  106. Yang C, Liu Y, Xi WQ, Zhou CF, Jiang JL, Ma T, et al. Relationship between UGT1A1∗6/∗28 polymorphisms and severe toxicities in chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug Des Devel Ther. 2015;9:3677–83.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Karmanos Cancer Institute, Detroit, MI, USA

    Anteneh Tesfaye

  2. Department of Oncology, Department of Pharmacology, Wayne State University, Karmanos Cancer Institute, Hudson-Webber Cancer Research Center, Detroit, MI, USA

    Philip A. Philip

Authors
  1. Anteneh Tesfaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip A. Philip
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anteneh Tesfaye .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Cancer, Sihhiye, Ankara, Turkey

    Suayib Yalcin

  2. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Philip A. Philip

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tesfaye, A., Philip, P.A. (2019). Treatment of Advanced Pancreatic Carcinoma. In: Yalcin, S., Philip, P. (eds) Textbook of Gastrointestinal Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-18890-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18890-0_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18888-7

  • Online ISBN: 978-3-030-18890-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation